RxDoctor Payments Data

Garo Terzian, MD

Internal Medicine · Burbank, CANPI 1700952090

Payments from drug & device makers

$435in general payments, 2019–2025

Across 11 payments — averaging $39.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$186
  • Shockwave Medical, Inc$126
  • Avanir Pharmaceuticals, Inc.$36
  • Sun Pharmaceutical Industries Inc.$25
  • Novo Nordisk$16
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$16
  • plus $30 from 3 others

What the payments were for

  • Consulting fees$17540%
  • Food & beverage$25960%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$435 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$81,180
Medicare patients
149
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate70$122,449
Diclofenac Potassium31$104,635
OzempicSemaglutide49$46,386
Metformin Er GastricMetformin Hcl36$37,540
Tavaborole30$34,653
EliquisApixaban43$31,410
Diclofenac Sodium119$30,531
JanuviaSitagliptin Phosphate44$24,881
VascepaIcosapent Ethyl78$24,860
JardianceEmpagliflozin28$21,513
LinzessLinaclotide22$19,165
Diflorasone Diacetate24$18,186
CreonLipase/Protease/Amylase17$17,783
Naproxen-Esomeprazole MagNaproxen/Esomeprazole Mag16$16,886
Dexlansoprazole DrDexlansoprazole81$15,796

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$15$51,03385 claims
AbbVieLinzess, Creon, Restasis$14$47,45356 claims
Novo NordiskOzempic$16$46,38649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →